



1/21

FIG. 1




HPLC CHROMATOGRAM OF Tc-99m-PEPTIDE 4

FIG. 2



HPLC CHROMATOGRAM OF Tc-99m-PEPTIDE 6


FIG. 3



DISTRIBUTION OF Tc-99m-PEPTIDE IN RABBIT BLOOD

FIG. 4

2 HRS. AFTER
ADMINISTRATION



22 HRS. AFTER
ADMINISTRATION





IMAGE OF Tc-99m-PEPTIDE 3 IN MODEL RABBIT WITH INFECTIOUS DISEASE

FIG. 5

2 HRS. AFTER
ADMINISTRATION



22 HRS. AFTER
ADMINISTRATION





IMAGE OF Tc-99m-PEPTIDE 4 IN MODEL RABBIT WITH INFECTIOUS DISEASE

FIG. 6

2 HRS. AFTER
ADMINISTRATION



22 HRS. AFTER
ADMINISTRATION




IMAGE OF Tc-99m-PEPTIDE 6 IN MODEL RABBIT WITH INFECTIOUS DISEASE

FIG. 7

2 HRS. AFTER
ADMINISTRATION



5 HRS. AFTER
ADMINISTRATION




IMAGE OF Tc-99m-PEPTIDE 8 IN MODEL RABBIT WITH INFECTIOUS DISEASE

5/21

FIG. 8

2 HRS. AFTER
ADMINISTRATION




5 HRS. AFTER
ADMINISTRATION



IMAGE OF Tc-99m-PEPTIDE 9 IN MODEL RABBIT WITH INFECTIOUS DISEASE

FIG. 9

2 HRS. AFTER
ADMINISTRATION



22 HRS. AFTER
ADMINISTRATION



IMAGE OF Tc-99m-PEPTIDE 12 IN MODEL RABBIT WITH INFECTIOUS DISEASE

6/21

FIG. 10




IMAGE OF Tc-99m-PEPTIDE 13 IN MODEL RABBIT WITH INFECTIOUS DISEASE

7/21

FIG. 11




IMAGE OF Tc-99m-PEPTIDE 14 IN MODEL RABBIT WITH INFECTIOUS DISEASE

8/21

FIG. 12



IMAGE OF Tc-99m-PEPTIDE 15 IN MODEL RABBIT WITH INFECTIOUS DISEASE

FIG. 13




IMAGE OF Tc-99m-PEPTIDE 16 IN MODEL RABBIT WITH INFECTIOUS DISEASE

10/21

FIG. 14




IMAGE OF Tc-99m-PEPTIDE 17 IN MODEL RABBIT WITH INFECTIOUS DISEASE

FIG. 15




IMAGE OF Tc-99m-PEPTIDE 18 IN MODEL RABBIT WITH INFECTIOUS DISEASE

FIG. 16



TIME COURSE CHANGE OF URINARY EXCRETION OF $Tc-99m$ -PEPTIDES IN NORMAL RATS

FIG. 17



TIME COURSE CHANGE OF ACCUMULATION OF $Tc-99m$ -PEPTIDES IN SMALL INTESTINE ON NORMAL RATS

FIG. 18





FIG. 19



14/21

FIG. 20

30 MIN. AFTER
ADMINISTRATION




120 MIN. AFTER
ADMINISTRATION



IMAGE OF Tc-99m LABELED PEPTIDE 3 IN MODEL RAT WITH COLITIS

FIG. 21

30 MIN. AFTER
ADMINISTRATION



120 MIN. AFTER
ADMINISTRATION




IMAGE OF Tc-99m LABELED PEPTIDE 6 IN MODEL RAT WITH COLITIS

FIG. 22






IMAGE OF Tc-99m LABELED LEUKOCYTES IN MODEL RAT WITH COLITIS

FIG. 23




INFLAMMATION/ORGAN RATIO OF Tc-99m LABELED PEPTIDE IN MODEL RAT WITH COLITIS

FIG. 24




IMAGES OF PEPTIDE 6 ON AUTORADIOGRAPHY AND IMMUNO-STAINING OF RAT WITH COLITIS

FIG. 25




IMAGES OF PEPTIDE 14 ON AUTORADIOGRAPHY AND IMMUNO-STAINING OF RAT WITH COLITIS

FIG. 26




IMAGES OF Tc-99m LABELED LEUKOCYTES ON AUTORADIOGRAPHY AND IMMUNO-STAINING OF RAT WITH COLITIS

FIG. 27



INFLAMMATION/NORMAL TISSUE RATIO OF AUTORADIOGRAPHY OF RAT WITH COLITIS USING Tc-99m LABELED PEPTIDE AND Tc-99m LABELED LEUKOCYTES

FIG. 28



INHIBITION RATE OF PEPTIDES FOR BINDING BETWEEN RECOMBINANT HUMAN RECEPTOR AND $[^3\text{H}]$ -FMLP

FIG. 29



IMAGE OF Tc-99m-PEPTIDE 6 IN MODEL RABBIT WITH INFECTIOUS
DISEASE WITHOUT INHIBITOR OF FMLP

FIG. 30




IMAGE OF Tc-99m-PEPTIDE 6 IN MODEL RABBIT WITH INFECTIOUS DISEASE WITH INHIBITION OF FMLP